A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin

Exclusion Criteria

• •Known or clinically suspected central nervous system (CNS) primary tumors or metastases including leptomeningeal metastases. History or clinical evidence of CNS metastases unless they have been previously treated, are asymptomatic and have had no requirement for steroids or enzyme-inducing anticonvulsants in the last 14 days
• •Evidence of significant uncontrolled concomitant diseases or disorders
• •Active or uncontrolled infections
• •Known Human immuno deficiency virus (HIV) infection
• •Therapy with antibody or immunotherapy concurrently or within 14 days prior to first dose of study drug
• •Regular immunosuppressive therapy
• •Concurrent high dose of systemic corticosteroids (greater than (\>) 20 milligrams per day \[mg/day\] dexamethasone or equivalent for \> 7 consecutive days)